Last reviewed · How we verify

NCT05611307

Late Subclinical Cardiovascular Disease in Testicular Cancer Survivors

Terminated Last updated 11 August 2025
What this trial tests

trial testing Lipid profile in Testicular Cancer in 31 participants. Terminated before completion.

Timeline
11 October 2022
Primary endpoint
4 December 2024
4 December 2024

Quick facts

Lead sponsorIndiana University
StatusTerminated
Study typeOBSERVATIONAL
Enrollment31
Start date11 October 2022
Primary completion4 December 2024
Estimated completion4 December 2024
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Indiana University

Who can join

Adults 18 to 99, male only, with Testicular Cancer or Survivorship. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Late subclinical cardiovascular disease in testicular cancer survivors exposed to cisplatin-based chemotherapy and bone marrow transplant

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Lipid profile

Trials testing the same drug.

Other recruiting trials for Testicular Cancer

Currently open trials in the same condition.

Other Indiana University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05611307.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing